How Mounjaro Can Affect Your Menstrual Cycle

Cycle changes reported on Mounjaro are most commonly linked to weight-loss-driven hormonal shifts, not a direct drug effect on reproductive hormones
Tirzepatide reduces absorption of oral contraceptives during the first four weeks of treatment and after each dose increase — additional contraception is recommended during those windows
Changes to periods are generally temporary and tend to settle as weight stabilises, though any unusual or persistent bleeding warrants a GP review
Women who are pregnant, breastfeeding or trying to conceive should not take Mounjaro; reliable contraception and discussion with a prescriber are essential before starting

Mounjaro (tirzepatide) can affect the menstrual cycle in some women, most often causing changes to timing, flow or regularity, particularly in the first months of treatment. These shifts appear to be linked to the hormonal ripple effects of significant weight loss rather than tirzepatide acting directly on reproductive hormones — though the research in this specific area is still developing. As a prescription-only medicine, Mounjaro requires clinical assessment before it is prescribed; a qualified prescriber will take your full medical picture into account, including any relevant gynaecological history.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence and clinical guidance say about tirzepatide and menstrual changes

You've started Mounjaro and your period is different, here's why that happens

Picture this: you're a few weeks into treatment, losing weight steadily, and your next period arrives a week early, or later than usual, or noticeably lighter. It's unsettling, and the first instinct is to wonder whether the pen in your fridge door is to blame.

The most likely explanation isn't a direct pharmaceutical effect on your uterus. Fat tissue is hormonally active, it produces and stores oestrogen. When body fat falls relatively quickly, oestrogen levels shift, and the hypothalamic-pituitary-ovarian axis, which orchestrates your cycle, can take time to recalibrate. Rapid weight loss from any cause (bariatric surgery, illness, other medicines) can produce the same temporary disruption. Mounjaro accelerates weight loss more than most interventions, so cycle changes are more commonly noticed by people using it.

There is also emerging interest in whether insulin sensitivity improvements (tirzepatide activates both GIP and GLP-1 receptors, affecting glucose regulation) may benefit women with polycystic ovary syndrome, for whom irregular cycles are often tied to insulin resistance. Some women with PCOS report more regular periods after starting treatment, and you can read more about how Mounjaro relates to menstrual bleeding on a dedicated page covering the topic in detail. That said, this is observational rather than the outcome of a dedicated randomised trial, so the clinical picture is still being built. The NHS tirzepatide medicines page is the clearest patient-level summary of what is currently confirmed about the medicine's effects.

Short-cycle disruption in the early months of treatment is commonly reported and generally self-limiting. If you want a fuller picture of whether and how Mounjaro affects your period, our dedicated page brings together what the evidence currently shows. If bleeding is heavier than normal, very prolonged, or absent for an unexpected period of time, speak to your GP rather than waiting it out, those patterns deserve their own investigation, separate from your weight-loss treatment.

The contraceptive pill question: why a prescriber will ask about this specifically

This is the area where the clinical guidance is clearest, and it matters practically. Because Mounjaro slows gastric emptying, it can reduce how much of an oral contraceptive tablet is absorbed in the first four weeks of treatment and for four weeks after each dose increase. NHS England's guidance on weight-management injections is explicit: women taking the combined or progesterone-only pill should use an additional non-oral method of contraception (condoms, for example) during those windows.

This is not a permanent arrangement. Once you have been stable on a given dose for four weeks, oral contraceptive absorption is expected to return to normal. Understanding how the tirzepatide dosing cycle works can help you keep track of exactly when those four-week windows begin and reset. A prescriber reviewing your consultation will flag this; if you are already taking Mounjaro and haven't discussed it, it is worth raising at your next review. You can read more about how Mounjaro interacts with the contraceptive pill on a dedicated page that goes into the detail.

Women using long-acting reversible contraception (the coil, implant or injection) are not affected by this absorption issue. HRT users may want to consider transdermal options (patches or gels rather than tablets) for similar reasons; there is more detail on Mounjaro and HRT if that applies to you.

Planning ahead: pregnancy, stopping treatment and the wash-out window

Mounjaro is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. That isn't a precaution peculiar to this medicine, the clinical trials that establish safety simply haven't included those populations, so the data to say it is safe in those situations doesn't exist. The guidance is to stop treatment and allow a wash-out period before attempting conception; your prescriber will advise on timing based on the specific dose and how long you have been taking it.

For women whose irregular cycles made conception difficult in the first place (particularly those with PCOS) improving cycle regularity through treatment could, counterintuitively, increase fertility before a pregnancy is planned. Reliable contraception throughout treatment is therefore essential, not optional. This is something to discuss openly at consultation rather than something to work out retrospectively.

If you are thinking about cost alongside all of this, it is worth understanding how Mounjaro pricing works in the UK private market before making a decision, price varies significantly by dose and provider, and what's included in the headline figure varies too.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not a routing algorithm) on the day you submit it. Cycle history and contraceptive use are part of that review. If questions come up once you have started treatment, our prescribers are available seven days a week. You can explore treatment options or speak to our prescribers to check your suitability.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions